Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present a range of studies at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, set to occur in Chicago and online from May 31 - June 4, 2024. Abstract titles are now available. Click on the links below to obtain more information.

ASCO will release the majority of abstracts on Thursday, May 23, at 5:00 PM (ET). Abstracts are under the ASCO news embargo until then. Please note specific embargo information for late-breaking (LBA) abstracts. Please follow the ASCO 2024 Annual Meeting Media Policies. 

Oral Presentations

Breast Cancer – Late-breaking abstract submission – A prospective trial that enrolled only Black women – ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Variants and Taxane Type in Association with Taxane-Induced Peripheral Neuropathy (TIPN) in Black Women with Early-Stage Breast Cancer. Tarah J. Ballinger, MD. Abstract LBA503. Obtain background information here.

Esophageal/Gastric Cancer – A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma - results of the neoadjuvant pathologic complete response (pCR) rate: ECOG-ACRIN EA2174. Jennifer R. Eads, MD. Abstract 4000.

Head and Neck Cancer – Follow-up on a practice-changing approach using less radiation – Selected for ASCO Clinical Science Symposium – Long-Term Follow-Up of E3311, A Phase 2 Trial of Transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer. Barbara A. Burtness, MD. Abstract 6009.

Pancreas Cancer – A new approach in geriatric oncology – A Randomized Phase 2 Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naive Metastatic Pancreatic Cancer (GIANT): ECOG-ACRIN EA2186. Efrat E. Dotan, MD. Abstract 4003. Obtain background information here.

Prostate Cancer – Late-breaking abstract submission – Cabazitaxel with Abiraterone versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: the CHAARTED2 Trial (EA8153). Christos P. Kyriakopoulos, MD. Abstract LBA5000. Obtain background information here.

Posters

Melanoma – A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) is significantly predictive of ICI immunotherapeutic benefits. Ahmad A. Tarhini, MD, PhD. Abstract 9568.

NCI-MATCH – Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E/K Mutations: Updated results from NCI-MATCH Arm H. April K.S. Salama, MD. Abstract 3110.

NCI-MATCH – Molecular profiling of plasma from matched NCI-MATCH gynecological cancers. Amanda Peach, MS (Bao Le, PhD, presenter). Abstract 5579. Note: ECOG-ACRIN researchers are co-authors of this abstract.

Prostate Cancer – Prognostic Validation of a Digital Pathology-Based Multi-Modal Artificial Intelligence (MMAI) Biomarker in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) from the CHAARTED Trial. Mark C. Markowski MD, PhD. Abstract 5077.

Prostate Cancer – Whole exome correlates in metastatic hormone sensitive prostate cancer (mHSPC): results from E3805 CHAARTED. Anis Hamid, MBBS. Abstract 5088.

Survivorship – EROS: Engendering reproductive health within oncologic survivorship—ECOG-ACRIN E1Q11 paradoxical provision of reproductive health. Ashlesha Patel, MD. Abstract 11123.

Survivorship – If you build it, they will come: Success of the EROS: Engendering Reproductive health within Oncologic Survivorship: ECOG-ACRIN E1Q11 in recruitment of minority patients. Ashlesha Patel, MD. Abstract 11124.

Publication

Survivorship – EROS: Engendering reproductive health within oncologic survivorship—ECOG-ACRIN E1Q11 assessing discrepancy in clinician-patient importance of sexuality over 2 years post-cancer diagnosis. Shivani Rao. Abstract e23197.

Trial in Progress

Breast Cancer – Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT Trial. Maeve Hennessy, MRCP. Abstract TPS614.